Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 18/20 | 1.00 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.74 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.74 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.74 |
| ▸ | CSF1R | P07333 | 1/20 | 0.74 |
| ▸ | PIM1 | P11309 | 1/20 | 0.74 |
| ▸ | CDK2 | P24941 | 1/20 | 0.74 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.74 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.74 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5274491 | 0.90 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1ROCK2PRKD3CSF1R | |
| SCHEMBL5274463 | 0.88 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1ROCK2PRKD3CSF1R | |
| SCHEMBL5269006 | 0.86 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1ROCK2PRKD3CSF1R | |
| SCHEMBL22331074 | 0.86 | HSP90AA1 (0.77) | HSP90AA1HSP90AB1ROCK2PRKD3CSF1R | |
| SCHEMBL3077043 | 0.85 | HSP90AA1 (0.74) | HSP90AA1HSP90AB1ROCK2PRKD3CSF1R | |
| SCHEMBL2684425 | 0.85 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1ROCK2PRKD3CSF1R | |
| SCHEMBL13591429 | 0.85 | HSP90AA1 (0.85) | HSP90AA1HSP90AB1ROCK2PRKD3CSF1R | |
| SCHEMBL13591432 | 0.85 | HSP90AA1 (0.85) | HSP90AA1HSP90AB1ROCK2PRKD3CSF1R | |
| SCHEMBL13591433 | 0.84 | HSP90AA1 (0.82) | HSP90AA1HSP90AB1ROCK2PRKD3CSF1R | |
| SCHEMBL5269011 | 0.84 | HSP90AA1 (0.85) | HSP90AA1HSP90AB1ROCK2PRKD3CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10744213-B2 | Fluorescent compounds for imaging of blood vessels and blood flow, and an in vivo screen for pro- and anti-angiogenic agents | COLOSSUS BIOPHARMA CONSULTANTS COMPANY, LIMITED (TW) | 2020-08-18 | — | — | US | disclosed |
| US-7632855-B2 | Pyrazole compounds as HSP90 inhibitors for the treatment of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2009-12-15 | — | — | US | disclosed |
| US-7632855-B2 | Pyrazole compounds as HSP90 inhibitors for the treatment of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2009-12-15 | — | — | US | disclosed |
| US-7632855-B2 | Pyrazole compounds as HSP90 inhibitors for the treatment of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2009-12-15 | — | — | US | disclosed |
| EP-1456180-B1 | 3-(2,4)DIHYDROXYPHENYL-4-PHENYLPYRAZOLES AND THEIR MEDICAL USE | VERNALIS CAMBRIDGE LTD (GB) | 2007-10-03 | — | — | EP | disclosed |
| EP-1456180-B1 | 3-(2,4)DIHYDROXYPHENYL-4-PHENYLPYRAZOLES AND THEIR MEDICAL USE | VERNALIS CAMBRIDGE LTD (GB) | 2007-10-03 | — | — | EP | disclosed |
| US-7247734-B2 | 3,4-diarylpyrazoles and their use in the therapy of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-07-24 | — | — | US | disclosed |
| US-7247734-B2 | 3,4-diarylpyrazoles and their use in the therapy of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-07-24 | — | — | US | disclosed |
| US-20070072855-A1 | 5-(5-Chloro-2,4-dihydroxy-phenyl)-4-(4-methoxy-phenyl)-2H-pyrazole-3-carboxylic acid, for example; for treatment of diseases which are mediated by excessive or inappropriate HSP90 activity, such as cancers | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-03-29 | — | — | US | disclosed |
| US-20070072855-A1 | 5-(5-Chloro-2,4-dihydroxy-phenyl)-4-(4-methoxy-phenyl)-2H-pyrazole-3-carboxylic acid, for example; for treatment of diseases which are mediated by excessive or inappropriate HSP90 activity, such as cancers | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-03-29 | — | — | US | disclosed |
| US-20070072855-A1 | 5-(5-Chloro-2,4-dihydroxy-phenyl)-4-(4-methoxy-phenyl)-2H-pyrazole-3-carboxylic acid, for example; for treatment of diseases which are mediated by excessive or inappropriate HSP90 activity, such as cancers | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-03-29 | — | — | US | disclosed |
| EP-1620090-A1 | PYRAZOLE COMPOUNDS AS HSP90 INHIBITORS FOR THE TREATMENT OF CANCER | Vernalis (Cambridge) Limited (GB) | 2006-02-01 | — | — | EP | disclosed |
| US-20050222230-A1 | 3,4-diarylpyrazoles and their use in the therapy of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2005-10-06 | — | — | US | disclosed |
| WO-2004096212-A9 | PYRAZOLE COMPOUNDS AS HSP90 INHIBITORS FOR THE TREATMENT OF CANCER | VERNALIS CAMBRIDGE LTD (GB) | 2005-03-31 | — | — | WO | disclosed |
| WO-2004096212-A1 | PYRAZOLE COMPOUNDS AS HSP90 INHIBITORS FOR THE TREATMENT OF CANCER | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| EP-1456180-A1 | 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER | Vernalis (Oxford) Ltd (GB) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003055860-A1 | 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10744213-B2 | Fluorescent compounds for imaging of blood vessels and blood flow, and an in vivo screen for pro- and anti-angiogenic agents | FLT4, VEGFA, FLT1 | HSP90AA1 2235/4885HSP90AB1 2342/4885ROCK2 453/4885 |
| US-20070072855-A1 | 5-(5-Chloro-2,4-dihydroxy-phenyl)-4-(4-methoxy-phenyl)-2H-pyrazole-3-carboxylic acid, for example; for treatment of diseases which are mediated by excessive or inappropriate HSP90 activity, such as cancers | HSP90AB1, HSP90AA1, NR5A2 | HSP90AA1 2/4885HSP90AB1 1/4885ROCK2 3202/4885 |
| US-20050222230-A1 | 3,4-diarylpyrazoles and their use in the therapy of cancer | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885HSP90AB1 1/4885ROCK2 3126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.